Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Vaxcyte, Inc. Common Stock

PCVX

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Last trade $59.57
Day change -$2.04 (-3.31%)
Day range $59.19 – $62.49
Volume 500,660
Market cap $9.75B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$9.75B
Price / earnings
—
Price / book
3.92×
Price / sales
—
EV / sales
—
EV / EBITDA
-8.09×

Profitability

Earnings per share
-$7.26
Return on assets
-38.42%
Return on equity
-46.14%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.04×
Current ratio
4.56×
Quick ratio
4.56×
Cash ratio
0.42×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$994.76M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PCVX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$37.95M$34.93M$33.07M$32.22M$32.45M$32.04M$32.66M$28.56M
Research and development$270.33M$267.85M$312.78M$242.06M$209.93M$194.18M$148.13M$133.61M
Total operating expenses$308.27M$302.78M$345.85M$274.28M$242.38M$226.22M$180.79M$162.17M
Operating income-$308.27M-$302.78M-$345.85M-$274.28M-$242.38M-$226.22M-$180.79M-$162.17M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$297.06M-$284.3M-$320.62M-$246.51M-$212.83M-$166.57M-$140.72M-$137.08M
Income taxes$0$0$0$0$0$0$0$0
Net income-$297.06M-$284.3M-$320.62M-$246.51M-$212.83M-$166.57M-$140.72M-$137.08M
Net income attributable to common shareholders-$297.06M-$284.3M-$320.62M-$246.51M-$212.83M-$166.57M-$140.72M-$137.08M
EBITDA-$302.5M-$299.78M-$342.9M-$258.32M-$239.32M-$223.34M-$177.84M-$150.46M
Basic earnings per share-$1.99-$1.97-$2.30-$1.81-$1.56-$1.22-$1.04-$1.01
Diluted earnings per share-$1.99-$1.97-$2.30-$1.81-$1.56-$1.22-$1.04-$1.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

Vaxcyte (PCVX) has a mean analyst price target of $117.30, suggesting 87.4% upside potential from its current $62.61 price. The stock has gained 11.7% over the past four weeks. While price targets should be viewed skeptically, the stock benefits from strong analyst agreement on positive earnings estimate revisions and holds a Zacks Rank #2 (Buy) rating, indicating potential near-term upside.

Zacks Investment Research

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Vaxcyte (PCVX) has gained 12.8% over the past four weeks and Wall Street analysts project a mean price target of $117.3, indicating a potential 75.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.

GlobeNewswire Inc.

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Vaxcyte, a clinical-stage vaccine company, announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds: 7.4 million shares of common stock at $64.00 per share and $500 million in convertible senior notes due 2032 with a 1.50% interest rate. The company plans to use net proceeds to fund clinical development of VAX-31 (31-valent pneumococcal conjugate vaccine) programs, manufacturing scale-up, commercial preparations for potential U.S. adult launch, and general corporate purposes. The offerings are expected to close on October 9, 2026.

Zacks Investment Research

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?

Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.

The Motley Fool

Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge

The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.